Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

Multiple Sclerosis Journal

Volumn 18, Issue 6, 2012, Pages 899-901

  Rispens, Theo ^a,b   Vennegoor, Anke ^c   Wolbink, Gert Jan ^a   Polman, Chris H ^c   Killestein, Joep ^c  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Disease modifying therapies; IgG4 antibody; multiple sclerosis; PML; Tysabri

Indexed keywords

DRUG ANTIBODY; NATALIZUMAB;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; HUMAN; MULTIPLE SCLEROSIS; RELAPSE; TREATMENT RESPONSE;

EID: 84861807320     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511431073     Document Type: Article

References (14)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
2. Clifford DB, De LA, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010 ; 9: 438-446
3. Warnke C, Menge T, Hartung HP, et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?. Arch Neurol. 2010 ; 67: 923-930
4. Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010 ; 68: 392-395
5. West TW, Cree BA.. Natalizumab dosage suspension: are we helping or hurting?. Ann Neurol. 2010 ; 68: 395-399
6. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009 ; 72: 402-409
7. Sheremata WA, Vollmer TL, Stone LA, et al. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology. 1999 ; 52: 1072-1074
8. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001 ; 121: 268-274
9. Rispens T, van Leeuwen A, Vennegoor A, et al. Measurement of serum levels of natalizumab, an IgG4 therapeutic monoclonal antibody. Anal Biochem. 2011 ; 411: 271-276
10. Labrijn AF, Buijsse AO, van den Bremer ET, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009 ; 27: 767-771
11. Shapiro RI, Plavina T, Schlain BR, et al. Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri) with endogenous IgG4. J Pharm Biomed Anal. 2011 ; 55: 168-175
12. Zack DJ, Stempniak M, Wong AL, et al. Localization of an Fc-binding reactivity to the constant region of human IgG4. Implications for the pathogenesis of rheumatoid arthritis. J Immunol. 1995 ; 155: 5057-5063
13. Rispens T, Ooievaar-De Heer P, Vermeulen E, et al. Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions. J Immunol. 2009 ; 182: 4275-4281
14. Vennegoor A, Wattjes MP, van Munster ET, et al. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology. 2011 ; 76: 574-576